Proposed case of mesalazine-induced cardiomyopathy in severe ulcerative colitis
Kathryn Fleming1, Andrew Ashcroft1, Christopher Alexakis1
1Kathryn Fleming, Andrew Ashcroft, Christopher Alexakis, Demitrios Tzias, Christopher Groves, Andrew Poullis, Department of Gastroenterology, St Georges Hospital, SW17 0QT London, United Kingdom.
Abstract:
Five-amino salicylic acids are recommended for use in the management of inflammatory bowel disease, cardiac complications are a rare although recognised phenomenon. This report aims to highlight this serious but rare adverse reaction. We report here a case of a young man presenting with cardiogenic shock in the context of recent mesalazine treatment in severe ulcerative colitis.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cardiomyopathy V: Interprofessional Care
Myocarditis I: Introduction


